The vice president of drug development startup Gateway Biotechnology, Inc. in St. Louis, Missouri, Thomas Brutnell draws on more than 25 years of experience in plant molecular biology, genetics, and genomics to conduct research into preventing and treating hearing loss. During Thomas Brutnell’s tenure with the company, Gateway Biotechnology was selected to participate in the 2019 MassChallenge Boston.
A prestigious accelerator program, MassChallenge is a network that operates in Boston, Austin, Houston, and Rhode Island, as well as internationally in Mexico, Switzerland, and Israel. Participating startups receive access to coworking space and mentoring, as well as the potential to connect with venture investors. Gateway was among just 9 percent of applicants selected for the program, giving the company a chance to compete for over $1 million in cash prizes.
MassChallenge Boston marks a significant opportunity for Gateway Biotechnology, which has previously received funding from Small Business Innovation Research and Small Business Technology. Gateway Biotechnology was also part of a $10 million Army grant to study hearing loss.
As an innovator in genomics technologies, Thomas Brutnell serves as the vice president of Gateway Biotechnology in St. Louis, Missouri. Drawing on over 25 years of molecular biology, genetics, and genomics experience, Thomas Brutnell oversees Gateway’s innovative drug research and development projects.
Founded in 2011, Gateway Biotechnology is a drug research company located in St. Louis. The company focuses on repurposing FDA-approved drugs for use in treating and preventing hearing disorders. Currently, there are no FDA-approved drug on the market for treating the majority of hearing problems that Gateway Biotechnology aims to address.
The company is currently conducting studies to deploy innovative solutions for noise-induced hearing loss and tinnitus. One of their projects, funded by the US Department of the Army, centers on developing effective treatments for noise-induced hearing loss and is now being tested in a clinical phase II trial. Gateway’s research pipeline has largely been driven through non-dilutive grants from the National Institute of Health’s Small Business Innovation Research SBIR and Small Business Technology Transfer STTR programs.
The company is now actively seeking investments to help accelerate the development of a product to protect against acute acoustic trauma.